Exact Sciences Corp.’s third-quarter report came in worse than analysts predicted, the Wisconsin State Journal reports. The Madison-based biomedical company, known for its Cologuard at-home colon cancer screening test, reported the results Tuesday.
The company saw a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million, while the average estimate of six analysts surveyed by Zacks Investment research was a $0.20 loss per share, and seven surveyed analysts projected $717.4 million in revenue.
Exact Sciences said it anticipates full-year revenue between $2.73 billion–$2.75 billion.
